ProCE Banner Series

ONC APPs Intensive: Adjuvant and Neoadjuvant Therapy in Early-Stage NSCLC: Best Practices for Safe and Effective Delivery of Care

Join us for this case-based, interactive, CE-certified live webinar featuring expert perspectives for nurses, nurse practitioners, and physician associates on treatment for patients with early-stage NSCLC. Be sure to bring your questions for the live question and answer session with the expert panel.

  AAPA
  | ANCC
Who Should Attend

This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients treated with neoadjuvant and/or adjuvant therapy in early-stage NSCLC.

All Events

ONC APPs Intensive: Adjuvant and Neoadjuvant Therapy in Early-Stage NSCLC: Best Practices for Safe and Effective Delivery of Care

Past Events

October

16

2024

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Faculty

ProCE Banner Faculty
Tiffany Apana, MSN, FNP-BC

Nurse Practitioner
Department of Thoracic Oncology
Moffitt Cancer Center
Tampa, Florida

ProCE Banner Faculty
Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge and competence in the management of patients treated with neoadjuvant and/or adjuvant therapy in early-stage NSCLC, including biomarker testing, application of treatment protocols, recognition and management of adverse events (AEs), and patient counseling to support informed decision-making and address barriers to care.

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients treated with neoadjuvant and/or adjuvant therapy in early-stage NSCLC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Summarize recommended biomarker testing for early-stage NSCLC and the relevance of testing to treatment selection, to facilitate discussions of testing with patients
  • Create strategies for the use of neoadjuvant therapy in patients with early NSCLC, personalizing therapy selection according to evidence, expert recommendations, and individual patient factors
  • Evaluate evidence for the role of individual patient and tumor characteristics for the use of adjuvant therapy in patients with resected NSCLC
  • Define perioperative therapy in early NSCLC and its potential application and benefits
  • Use appropriate supportive care, proactive management of treatment-related toxicities, and patient counseling to address adverse events and barriers to optimal care

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour, including 1.0 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Disclosure of Conflicts of Interest
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies.

Acknowledgement

Provided by Partners for Advancing Clinical Education (PACE) in partnership with Practicing Clinicians Exchange, LLC and Clinical Care Options, LLC

Supported by an educational grant from Merck Sharp & Dohme LLC.